Susceptibilities of multidrug-resistant pathogens responsible for complicated skin and soft tissue infections to standard bacteriophage cocktails;Komplike Deri ve Yumuşak Doku Enfeksiyonu Etkeni Çoklu Dirençli Patojenlerin Standart Bakteriyofaj Kokteyllerine Karşi Duyarliliklannin Araştinlmasi

Mikrobiyoloji Bulteni

Volumn 50, Issue 2, 2016, Pages 215-223

  Gündoǧdu, Aycan ^a   Kiliç, Hüseyin ^a   Ulu Kiliç, Ayşegül ^a   Kutateladze, Mzia ^b  

^a ERCIYES UNIVERSITY   (Turkey)

^b George Eliava Institute of Bacteriophage Microbiology and Virology   (Georgia)

Author keywords

Bacteriophage therapy; Complicated skin and soft tissue infection; Multidrug resistance

Indexed keywords

BACTERIOPHAGE; DRUG EFFECTS; ESCHERICHIA COLI; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MULTIDRUG RESISTANCE; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; VIROLOGY;

BACTERIOPHAGES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PSEUDOMONAS AERUGINOSA; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 84977142926     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: 10.5578/mb.24165     Document Type: Article

References (17)

1. White B, Seaton RA Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin. Infect Drug Resist 2011; 4:115-27.
2. Dryden M. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010; 65 Suppl 3: iii35-44.
3. Reardon S. Phage therapy gets revitalized. Nature 2014; 510(7503): 15-6.
4. Abedeon ST, Kuhl, SJ, Blasdel B.C., Kutter EM. Phage treatment of human infections. Bacteriophage 2011; 1(2): 66-85.
5. Lu TK, Koeris MS The next generation of bacteriophage therapy. Curr Opin Microbiol 2011; 14(5): 524-31.
6. Şahin F, Karasartova D., Özsan TM, Gerçeker D, Kiyan M. Klinik MRSA izolatlanndan elde edilen yeni bir litik bakteriyofajin tanimlanmasi ve antibakteriyel etkisinin deǧerlendirilmesi. Mikrobiyol Bui 2013; 47(1): 27-34.
7. Yilmaz C, Colak M, Yilmaz B.C., Ersoz C., Kutateladze M, Gozlugol M. Bacteriophage therapy in implant-related infections: an experimental study. J Bone Joint Surg Am 2013; 95(2): 117-25.
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-Fourth Informational Supplement. CLSI Document M100-S24, 2014. CLSI, Wayne, PA.
9. Adams MH. Bacteriophages. 1959, Interscience Publishers, New York.
10. Kutateladze M. Experience of the Eliava Institute in bacteriophage therapy. Virol Sin 2015; 30(1): 80-1.
11. Kanatli U. Diyabetik ayak enfeksiyonlari. TOTBiD Dergisi 2011; 10(4): 296-305.
12. Carson CF, Riley TV Non-antibiotic therapies for infectious diseases. Commun Dis Intell Q Rep 2003; 27 Suppl: S143-6.
13. Matsuzaki S, Rashel M, Uchiyama J., et al. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 2005; 11 (5): 211-9.
14. Fitzgerald-Hughes D., Bolkvadze D, Balarjishvili N., et al. Susceptibility of extended-spectrum- β-lactamase-producing Escherichia coli to commercially available and laboratory-isolated bacteriophages. J Antimicrob Chemother 2014; 69(4): 1148-50.
15. Merabishvili M, Pirnay JP, Verbeken G, et al Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009; 4(3): e4944.
16. Rhoads DD, Wolcott RD, Kuskowski M.A., Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 2009; 18(6): 237-8, 240-3.
17. Wright A, Hawkins CH, Anggard E.E., Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009; 34(4): 349-57.